Nuvectis Pharma, Inc.
General ticker "NVCT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $137.0M (TTM average)
Nuvectis Pharma, Inc. does not follow the US Stock Market performance with the rate: -16.8%.
Estimated limits based on current volatility of 4.6%: low 5.96$, high 6.54$
Factors to consider:
- Total employees count: 13 (0.0%) as of 2024
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Insufficient funding, Regulatory and compliance, Healthcare policy changes, Labor/talent shortage/retention, Cybersecurity threats
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.19$, 8.53$]
- 2025-12-31 to 2026-12-31 estimated range: [3.06$, 8.12$]
Financial Metrics affecting the NVCT estimates:
- Positive: with PPE of -4.4 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -14.66 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Shareholder equity ratio, % of 0 <= 18.93
- Negative: negative Net income
Short-term NVCT quotes
Long-term NVCT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $19.23MM | $22.90MM | $19.85MM |
| Operating Income | $-19.23MM | $-22.90MM | $-19.85MM |
| Non-Operating Income | $0.15MM | $0.64MM | $0.85MM |
| R&D Expense | $13.23MM | $15.38MM | $12.92MM |
| Income(Loss) | $-19.09MM | $-22.26MM | $-19.00MM |
| Profit(Loss)* | $-19.09MM | $-22.26MM | $-19.00MM |
| Stockholders Equity | $14.22MM | $12.20MM | $0.00MM |
| Assets | $20.41MM | $19.18MM | $18.61MM |
| Operating Cash Flow | $-13.56MM | $-15.95MM | $-12.25MM |
| Financing Cash Flow | $27.81MM | $15.09MM | $11.65MM |
| Earnings Per Share** | $-1.51 | $-1.43 | $-1.11 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.